NCT02723955 : Clinical Trial Detail - Cancer Knowledgebase (CKB)

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT02723955
Title	Dose Escalation and Expansion Study of GSK3359609 in Subjects With Selected Advanced Solid Tumors (INDUCE-1)
Recruitment	Completed
Gender	both
Phase	Phase I
Variant Requirements	No
Sponsors	GlaxoSmithKline
Indications	bladder carcinoma colorectal cancer squamous cell carcinoma melanoma head and neck carcinoma esophageal carcinoma lung non-small cell carcinoma malignant pleural mesothelioma colon carcinoma cervix carcinoma prostate carcinoma
Therapies	GSK3359609 GSK3359609 + Pembrolizumab
Age Groups:	child
Covered Countries	USA \| NLD \| ITA \| FRA \| ESP \| CAN \| AUS

NCT02723955
Clinical Trial Detail